KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Income for 13 consecutive years, with -$111.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 57.67% to -$111.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$352.1 million through Dec 2025, down 47.12% year-over-year, with the annual reading at -$352.1 million for FY2025, 47.12% down from the prior year.
  • Net Income for Q4 2025 was -$111.4 million at Xenon Pharmaceuticals, down from -$90.9 million in the prior quarter.
  • The five-year high for Net Income was $129.7 million in Q4 2023, with the low at -$111.4 million in Q4 2025.
  • Average Net Income over 5 years is -$34.1 million, with a median of -$44.6 million recorded in 2023.
  • The sharpest move saw Net Income crashed 12533.71% in 2021, then surged 428.18% in 2022.
  • Over 5 years, Net Income stood at -$25.6 million in 2021, then soared by 428.18% to $83.9 million in 2022, then soared by 54.65% to $129.7 million in 2023, then tumbled by 154.47% to -$70.7 million in 2024, then plummeted by 57.67% to -$111.4 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$111.4 million, -$90.9 million, and -$84.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.